Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atogepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 13/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atogepant SCHEMBL19750880 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL30603188 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL22259545 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL29371653 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL31611055 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL16652662 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Atogepant SCHEMBL16653283 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Atogepant SCHEMBL16653020 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Atogepant SCHEMBL35210098 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Atogepant SCHEMBL16652952 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| CN-112022818-A | Tablet formulations of CGRP-active compounds | 默沙东公司 | 2020-12-04 | — | — | CN | claimed |
| CN-105960397-B | Tablet formulations of CGRP-active compounds | 默沙东公司 | 2020-09-04 | — | — | CN | claimed |
| US-20190209478-A1 | TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-07-11 | — | — | US | claimed |
| US-10117836-B2 | Tablet formulation for CGRP active compounds | MERCK SHARP & DOHME CORP. (US) | 2018-11-06 | — | — | US | claimed |
| US-20160346214-A1 | TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-12-01 | — | — | US | claimed |
| US-20160346198-A1 | NOVEL DISINTEGRATION SYSTEMS FOR PHARMACEUTICAL DOSAGE FORMS | MERCK SHARP & DOHME CORP. (US) | 2016-12-01 | — | — | US | claimed |
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260014127-A1 | METHODS OF TREATING MIGRAINE | ALLERGAN PHARMACEUTICALS INT LTD (IE) | 2026-01-15 | — | — | US | disclosed |
| US-12465598-B2 | Methods of treating migraine | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2025-11-11 | — | — | US | disclosed |
| US-12458632-B2 | Treatment of migraine | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12350259-B2 | Methods of treating migraine | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2025-07-08 | — | — | US | disclosed |
| EP-2638042-B1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8754096-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-06-17 | — | — | US | disclosed |
| WO-2013138418-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-8481556-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Merck, Sharp & Dohms, Corp. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346214-A1 | TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 23/4885 |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
| US-12350259-B2 | Methods of treating migraine | PDE3A, PDE2A, PDE3B | CALCRL 478/4885RAMP1 959/4885 |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
| US-12465598-B2 | Methods of treating migraine | PDE3A, PDE2A, PDE3B | CALCRL 478/4885RAMP1 959/4885 |
| US-20160346198-A1 | NOVEL DISINTEGRATION SYSTEMS FOR PHARMACEUTICAL DOSAGE FORMS | SBDS, SI, DSP | CALCRL 3803/4885RAMP1 4573/4885 |
| US-12458632-B2 | Treatment of migraine | ABCB1, GABARAP, GABARAPL2 | CALCRL 188/4885RAMP1 56/4885 |
| US-20260014127-A1 | METHODS OF TREATING MIGRAINE | CYP2D6, CYP3A43, CYP3A5 | CALCRL 3139/4885RAMP1 274/4885 |
| US-10117836-B2 | Tablet formulation for CGRP active compounds | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 23/4885 |
| US-20190209478-A1 | TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 20/4885 |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.